Anti-Chol-1 Antigen, GQ1bα, Antibodies Are Associated with Alzheimer’s Disease

The interaction of amyloid β-proteins (Aβ) with membrane gangliosides has been reported to be an early event in Aβ fibril formation in Alzheimer’s disease (AD). Neuronal degeneration in AD has been postulated to be associated with the presence of anti-ganglioside antibodies in patient sera. Using an enzyme-linked immunosorbent assay (ELISA) and high-performance thin-layer chromatography (HPTLC) immunostaining, sera from 27 individuals (10 with AD, 6 with vascular dementia (VD), and 11 non-demented age-matched pathological controls) were examined in order to detect anti-glycosphingolipid (GSL) antibodies, including anti-cholinergic-specific antigen (Chol-1α; GQ1bα) antibodies. All sera had natural antibodies against ganglio-N-tetraosyl gangliosides (brain-type gangliosides). However, sera of demented patients with AD and VD had significantly higher titers of anti-GSL antibodies than those in age-matched pathological controls. Although most serum antibodies, including anti- GM1, -GT1b, -GQ1b, -GQ1bα, were of the IgM type, the presence of the IgG type antibodies was also significantly elevated in the sera of demented patients with AD. Anti-GT1b antibodies of the IgG type were elevated in AD (90%, 9 of 10 cases) and VD (100%), respectively. Most surprisingly, anti-GQ1bα antibodies (IgM) were found in 90% (9/10) and 100% (6/6) in the sera of patients with AD and VD, respectively. Since GQ1bα is present in the cerebral cortex and hippocampus, the presence of anti-GQ1bα antibodies may play an important role in disrupting cholinergic synaptic transmission and may participate in the pathogenesis of dementia. We conclude that elevated anti-GSL antibody titers may be useful as an aid for clinical diagnosis of those dementias.

[1]  O. Andersen,et al.  Myelin glycosphingolipid immunoreactivity and CSF levels in multiple sclerosis , 2012, Acta neurologica Scandinavica.

[2]  T. Kanda,et al.  Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood–brain barrier function , 2010, Journal of cellular physiology.

[3]  J. Buccafusco,et al.  Ganglioside metabolism in a transgenic mouse model of Alzheimer's disease: expression of Chol-1α antigens in the brain , 2010, ASN neuro.

[4]  T. Miyatake,et al.  Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: Amyloidogenesis and therapeutic strategies—A review , 2010, Journal of neuroscience research.

[5]  Marko Vuskovic,et al.  Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. , 2009, Molecular immunology.

[6]  Bruce D. Trapp,et al.  Axonal degeneration and progressive neurologic disability in multiple sclerosis , 2009, Neurotoxicity Research.

[7]  B. Kálmán,et al.  Autoantibodies and neurodegeneration in multiple sclerosis , 2008, Laboratory Investigation.

[8]  M. P. McDonald,et al.  Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease--a review. , 2008, Journal of lipid research.

[9]  J. Geiger,et al.  Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease , 2008, Journal of Neuroinflammation.

[10]  Stavros J. Baloyannis,et al.  Antibodies Against GM1 in Demented Patients , 2008, American journal of Alzheimer's disease and other dementias.

[11]  T. Ariga,et al.  Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains , 2007, Journal of neurochemistry.

[12]  M. D'Andrea,et al.  Aβ peptides can enter the brain through a defective blood–brain barrier and bind selectively to neurons , 2007, Brain Research.

[13]  P. Carvey,et al.  Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy , 2007, Cell transplantation.

[14]  S. Mori,et al.  Passive Immunization with Anti-Ganglioside Antibodies Directly Inhibits Axon Regeneration in an Animal Model , 2007, The Journal of Neuroscience.

[15]  R. Yu,et al.  Ganglioside Molecular Mimicry and Its Pathological Roles in Guillain-Barré Syndrome and Related Diseases , 2006, Infection and Immunity.

[16]  M. Acler,et al.  Anti-GD2-like IgM autoreactivity in multiple sclerosis patients , 2006, Multiple sclerosis.

[17]  T. S. Saravanan,et al.  Human Antiganglioside Autoantibodies: Validation of ELISA , 2005, Annals of the New York Academy of Sciences.

[18]  J. Raphaël,et al.  [Guillain-Barré syndrome]. , 2005, La Revue du praticien.

[19]  K. Majtényi,et al.  Serum IgG and IgM ganglioside GM1 antibodies in patients with multiple sclerosis. , 2004, Ideggyogyaszati szemle.

[20]  B. Winblad,et al.  Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer's disease , 1987, Journal of Neurology.

[21]  S. Cook,et al.  Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis , 2003, Journal of Neuroimmunology.

[22]  R. Nussbaum,et al.  Alzheimer's disease and Parkinson's disease. , 2003, The New England journal of medicine.

[23]  M. Pender,et al.  Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis , 2003, Journal of Clinical Neuroscience.

[24]  M Zappia,et al.  Anti‐GM1 ganglioside antibodies in Parkinson's disease , 2002, Acta neurologica Scandinavica.

[25]  S. McQuaid,et al.  Abnormal Endothelial Tight Junctions in Active Lesions and Normal‐appearing White Matter in Multiple Sclerosis , 2002, Brain pathology.

[26]  T. Kanda,et al.  Anti-GM1 antibody facilitates leakage in an in vitro blood–nerve barrier model , 2000, Neurology.

[27]  N. Yuki,et al.  Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barré syndrome with antiganglioside antibodies , 2000, Journal of neurology, neurosurgery, and psychiatry.

[28]  A. Mosek,et al.  Dementia and Antiphospholipid Antibodies , 2000, Dementia and Geriatric Cognitive Disorders.

[29]  F. Lolli,et al.  Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD I a , 1999, Multiple sclerosis.

[30]  M. Pender,et al.  Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis , 1998, Annals of neurology.

[31]  G. Nores,et al.  Anti‐GM1 ganglioside igm‐antibodies present in human plasma: Affinity and biological activity changes in a patient with neuropathy , 1998, Journal of neuroscience research.

[32]  N. Yuki,et al.  Antibodies to fucogangliosides in neurological diseases , 1997, Journal of the Neurological Sciences.

[33]  X. Montalban,et al.  Different antiganglioside antibody pattern between relapsing‐remitting and progressive multiple sclerosis , 1996, Acta neurologica Scandinavica.

[34]  A. Batra,et al.  Autoantibody reactivity in serum of patients with alzheimer's disease and other age-related dementias , 1996, Psychiatry Research.

[35]  H. Wiegandt,et al.  Characterization of anti-ganglioside antibodies present in normal human plasma , 1994, Journal of Neuroimmunology.

[36]  R. Yu,et al.  Development regulation of ganglioside metabolism. , 1994, Progress in brain research.

[37]  R. A. Klein,et al.  O-acetylated gangliosides in bovine buttermilk. Characterization of 7-O-acetyl, 9-O-acetyl, and 7,9-di-O-acetyl GD3. , 1992, The Journal of biological chemistry.

[38]  V. P. Whittaker,et al.  Structural characterization of a novel cholinergic neuron-specific ganglioside in bovine brain. , 1992, The Journal of biological chemistry.

[39]  V. P. Whittaker,et al.  A trisialoganglioside containing a sialyl α2-6 N-acetylgalactosamine residue is a cholinergic-specific antigen, chol-1α , 1992 .

[40]  V. P. Whittaker,et al.  A trisialoganglioside containing a sialyl alpha 2-6 N-acetylgalactosamine residue is a cholinergic-specific antigen, Chol-1 alpha. , 1992, Journal of biochemistry.

[41]  E. Derrington,et al.  The developmental expression of the cholinergic-specific antigen Chol-1 in the central and peripheral nervous system of the rat. , 1990, Brain research. Developmental brain research.

[42]  D. Michaelson,et al.  Antibodies to Cholinergic Neurons in Alzheimer's Disease , 1988, Journal of neurochemistry.

[43]  D. Michaelson,et al.  Antibodies to ganglioside GM1 in patients with Alzheimer's disease , 1988, Neuroscience Letters.

[44]  S. Kusunoki,et al.  Subcellular Localization of Sulfated Glucuronic Acid‐Containing Glycolipids Reacting with Anti‐Myelin‐Associated Glycoprotein Antibody , 1987, Journal of neurochemistry.

[45]  R. Yu,et al.  Isolation and characterization of ganglioside GM1b from normal human brain. , 1987, Journal of lipid research.

[46]  N. Kasai,et al.  Anti-glycolipid antibodies and their immune complexes in multiple sclerosis , 1986, Journal of the Neurological Sciences.

[47]  N. Latov,et al.  The neuropathy of plasma cell dyscrasia , 1985, Neurology.

[48]  T. Miyatake,et al.  Isolation and characterization of a novel disialoganglioside from bovine adrenal medulla. , 1984, Archives of biochemistry and biophysics.

[49]  T. Yasuda,et al.  Activation of the alternative complement pathway by natural antibody to glycolipids in guinea-pig serum. , 1983, Immunology.

[50]  R. Yu,et al.  Isolation and characterization of a novel trisialoganglioside, GT1a, from human brain. , 1977, The Journal of biological chemistry.